TDMS Study 88133-06 Pathology Tables
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE Date: 10/30/02
Route: SKIN APPLICATION Time: 10:08:32
Final#3
Facility: Battelle Columbus Laboratory
Chemical CAS #: 15625-89-5
Lock Date: 06/16/99
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include 002 0 MG/KG
Include 001 0 MG/KG
Include 004 0.75 MG/KG
Include 003 0.75 MG/KG
Include 006 1.5 MG/KG
Include 005 1.5 MG/KG
Include 008 3 MG/KG
Include 007 3 MG/KG
Include 010 6 MG/KG
Include 009 6 MG/KG
Include 012 12 MG/KG
Include 011 12 MG/KG
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE Date: 10/30/02
Route: SKIN APPLICATION Time: 10:08:32
____________________________________________________________________________________________________________________________________
TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 15 15 15 15 15 15
Early Deaths
Natural Death 1 2 1 1 3
Moribund Sacrifice 1
Survivors
Terminal Sacrifice 15 14 12 14 14 12
Animals Examined Microscopically 15 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (15) (15) (15) (15) (15) (15)
Salivary Glands (1) (1)
Carcinoma 1 (100%)
Stomach, Forestomach (15) (15) (15) (15) (15) (15)
Squamous Cell Papilloma 3 (20%) 4 (27%) 3 (20%) 1 (7%) 4 (27%) 6 (40%)
Squamous Cell Papilloma, Multiple 1 (7%) 1 (7%) 1 (7%) 1 (7%) 1 (7%) 3 (20%)
Tooth (1) (4) (3) (1) (3) (2)
Odontogenic Tumor 1 (100%) 4 (100%) 2 (67%) 3 (100%) 1 (50%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (15) (15) (15) (15) (15) (15)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Pituitary Gland (15) (15) (15) (15) (15) (15)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE Date: 10/30/02
Route: SKIN APPLICATION Time: 10:08:32
____________________________________________________________________________________________________________________________________
TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (15) (15) (15) (15) (15) (15)
Uterus (15) (15) (15) (15) (15) (15)
Vagina (1)
Squamous Cell Papilloma 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (11) (14) (13) (10) (13) (12)
Lymph Node, Mandibular (15) (15) (15) (15) (15) (15)
Lymph Node, Mesenteric (15) (14) (14) (15) (15) (15)
Spleen (15) (15) (15) (15) (15) (15)
Thymus (15) (15) (15) (15) (15) (15)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (15) (15) (15) (15) (15) (15)
Squamous Cell Papilloma 1 (7%) 1 (7%)
Skin, Site of Application, Squamous Cell
Carcinoma 1 (7%) 1 (7%) 1 (7%)
Skin, Site of Application, Squamous Cell
Papilloma 1 (7%) 6 (40%)
Skin, Site of Application, Squamous Cell
Papilloma, Multiple 5 (33%) 15 (100%)
Vulva, Squamous Cell Papilloma 1 (7%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (1)
Osteosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE Date: 10/30/02
Route: SKIN APPLICATION Time: 10:08:32
____________________________________________________________________________________________________________________________________
TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (15) (15) (15) (15) (15) (15)
Alveolar/Bronchiolar Adenoma 1 (7%) 1 (7%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (15) (15) (15) (15) (15) (15)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(15) *(15) *(15) *(15) *(15) *(15)
Leukemia Erythrocytic 1 (7%) 1 (7%) 2 (13%)
Lymphoma Malignant 1 (7%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 4
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE Date: 10/30/02
Route: SKIN APPLICATION Time: 10:08:32
____________________________________________________________________________________________________________________________________
TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 6 9 6 5 12 15
Total Primary Neoplasms 7 13 7 6 21 29
Total Animals with Benign Neoplasms 5 5 4 4 11 15
Total Benign Neoplasms 5 7 4 5 17 24
Total Animals with Malignant Neoplasms 1 2 1 1 1 3
Total Malignant Neoplasms 1 2 1 1 1 4
Total Animals with Metastatic Neoplasms
Total Metastatic Neoplasm
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1 4 2 3 1
Total Uncertain Neoplasms 1 4 2 3 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 5
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE Date: 10/30/02
Route: SKIN APPLICATION Time: 10:08:32
____________________________________________________________________________________________________________________________________
TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 15 15 15 15 15 15
Early Deaths
Natural Death 1 3 1 2 4
Survivors
Terminal Sacrifice 14 15 12 14 13 11
Animals Examined Microscopically 15 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (15) (15) (15) (15) (15) (15)
Salivary Glands (1) (1) (2)
Carcinoma 1 (100%) 1 (100%) 1 (50%)
Stomach, Forestomach (15) (15) (15) (15) (15) (15)
Squamous Cell Papilloma 3 (20%) 4 (27%) 1 (7%) 2 (13%) 2 (13%) 2 (13%)
Squamous Cell Papilloma, Multiple 2 (13%) 3 (20%) 2 (13%) 1 (7%)
Tooth (1) (3) (1) (2) (1) (1)
Odontogenic Tumor 1 (100%) 3 (100%) 1 (100%) 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (15) (15) (15) (15) (15) (15)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Pituitary Gland (15) (15) (15) (14) (15) (15)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 6
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE Date: 10/30/02
Route: SKIN APPLICATION Time: 10:08:32
____________________________________________________________________________________________________________________________________
TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (13) (13) (14) (15) (14) (14)
Lymph Node, Mandibular (15) (14) (15) (15) (14) (13)
Lymph Node, Mesenteric (15) (14) (14) (15) (15) (12)
Spleen (15) (15) (15) (15) (15) (15)
Thymus (15) (15) (14) (15) (15) (15)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (15) (15) (15) (15) (15) (15)
Squamous Cell Papilloma 2 (13%)
Skin, Site of Application, Squamous Cell
Papilloma 2 (13%)
Skin, Site of Application, Squamous Cell
Papilloma, Multiple 12 (80%) 13 (87%)
Subcutaneous Tissue, Fibrosarcoma 1 (7%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (15) (15) (15) (15) (15) (14)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE Date: 10/30/02
Route: SKIN APPLICATION Time: 10:08:32
____________________________________________________________________________________________________________________________________
TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (15) (15) (15) (15) (15) (15)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(15) *(15) *(15) *(15) *(15) *(15)
Leukemia Erythrocytic 1 (7%)
Lymphoma Malignant 1 (7%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 8
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE Date: 10/30/02
Route: SKIN APPLICATION Time: 10:08:32
____________________________________________________________________________________________________________________________________
TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 6 8 4 6 12 13
Total Primary Neoplasms 6 10 4 8 16 20
Total Animals with Benign Neoplasms 5 7 1 5 12 13
Total Benign Neoplasms 5 7 1 6 15 17
Total Animals with Malignant Neoplasms 2 1 2
Total Malignant Neoplasms 2 2 2
Total Animals with Metastatic Neoplasms
Total Metastatic Neoplasm
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1 3 1 1 1
Total Uncertain Neoplasms 1 3 1 1 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 9
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------